Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 441-445
DOI: 10.4103/ijmpo.ijmpo_192_20
Editorial Commentary

COVID-19 Management: What We Need to Know?

Manikandan Dhanushkodi
1   Department of Medical Oncology, Cancer Institute (WIA), Chennai, Tamil Nadu, India
,
Padmaj Kulkarni
2   Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Introduction

The world is plagued by the COVID-19 pandemic. This is an unprecedented situation in the modern era wherein we do not know our enemy in detail. In fact, we hardly know anything. We have just started to learn about COVID-19; the management guidelines are evolving and are mostly consensus based at present, rather than randomized data. In this article, we will briefly review some important updates and evolving research in the management of COVID-19.



Publication History

Received: 25 April 2020

Accepted: 01 May 2020

Article published online:
17 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z. et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med 2020; 382: 1177-9
    CrossrefPubMedGoogle Scholar
  • 2 Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC. et al. Diagnosing COVID-19: The disease and tools for detection. ACS Nano 2020; 14: 3822-35
    CrossrefPubMedGoogle Scholar
  • 3 COVID-19 Indian Council of Medical Research Government of India. https://icmr.nic.in/content/covid-19 Available from: [Last accessed on 2020 Apr 15]
  • 4 Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): A review. JAMA 2020; 323: 1824-36
    PubMedGoogle Scholar
  • 5 Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020 NEJMoa2007016 DOI: 10.1056/NEJMoa2007016. et al. Apr 10 Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 6 Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G. et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020; 382: 1787-99
    CrossrefPubMedGoogle Scholar
  • 7 Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20 105949 DOI: 10.1016/j.ijantimicag.2020.105949. et al. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 8 Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L. et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect 2020; 50: 384
    CrossrefPubMedGoogle Scholar
  • 9 Moore N. Chloroquine for COVID-19 Infection. Drug Saf 2020; 43: 393-4
    CrossrefPubMedGoogle Scholar
  • 10 Wu Y, Wang T, Guo C, Zhang D, Ge X, Huang Z. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. QJM 2020 Apr 10 hcaa121 DOI: 10.1093/qjmed/hcaa121. et al. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 11 Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM. et al. Convalescent plasma: New evidence for an old therapeutic tool?. Blood Trans 2016; 14: 152-7
    Google Scholar
  • 12 Duan K, Liu B, Li C, Zhang H, Yu T, Qu J. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A 2020; 117: 9490-6
    CrossrefPubMedGoogle Scholar
  • 13 Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J. et al. Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma. JAMA 2020; 323: 1582-9
    CrossrefPubMedGoogle Scholar
  • 14 Leo L. ICMR Seeks Participation for Trial of Plasma Therapy for Covid-19 Treatment. 2020 https://www.livemint.com/news/india/icmr-seeks-participation-for-trial-of-plama-therapy-for-covid-19-treatment-11586784202205.html Available from: [Last accessed on 2020 Apr 15]
    PubMedGoogle Scholar
  • 15 Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 06.04.2020; DOI: 10.1002/jmv.25801. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 16 Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020 Mar 13 e200994 DOI: 10.1001/jamainternmed.2020.0994. et al. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 17 Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395: 683-4
    CrossrefPubMedGoogle Scholar
  • 18 Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18: 1094-9
    CrossrefPubMedGoogle Scholar
  • 19 Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E. et al. Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med 2020; 46: 854-87
    CrossrefPubMedGoogle Scholar
  • 20 http://HCQ_Recommendation_22March_final_MM_V2.pdf Available from: [Last accessed on 2020 Apr 15]
  • 21 Cansu DÜ, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology (Oxford) 2008; 47: 378-9
    CrossrefPubMedGoogle Scholar
  • 22 Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila) 2006; 44: 173-5
    CrossrefPubMedGoogle Scholar
  • 23 Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: Key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care 2013; 2: 77-83
    CrossrefPubMedGoogle Scholar
  • 24 Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020 Mar 9 ciaa237 DOI: 10.1093/cid/ciaa237. et al. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 25 Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19) - Full Text View - ClinicalTrials. https://clinicaltrials.gov/ct2/show/NCT04318444 Available from: [Last accessed on 2020 Apr 15]
    Google Scholar
  • 26 Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis 17.04.2020; DOI: 10.1016/S1473-3099(20)30313-3. Online ahead of print
    CrossrefPubMedGoogle Scholar
  • 27 Lurie N, Saville M, Hatchett R, Halton J. Developing covid-19 vaccines at pandemic speed. New England J Med 2020; 382: 1969-73
    CrossrefPubMedGoogle Scholar